Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 1,694 trials

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Heart Failure: JTT-861 Medication Study

We are evaluating a new medication, JTT-861, for individuals with heart failure with reduced ejection fraction. The study aims to see if it is safe and effective in improving heart function.

Heart Failure with Reduced Ejection FractionEfficacy phase (II)Investigational MedicinesCost ReimbursementCardiologyInternal Medicine

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Fecal Microbiota Transplantation for Axial Spondyloarthritis

We are studying whether fecal microbiota transplantation can improve symptoms in patients with axial spondyloarthritis who haven't responded to standard treatments. This trial compares the effects of FMT to a placebo treatment.

Axial Spondyloarthritis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteGastroenterologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

High Cardiovascular Risk: Rosuvastatin vs. Combination Therapy

We are studying whether high-intensity rosuvastatin or a combination of rosuvastatin and ezetimibe can effectively lower cholesterol in patients at high or very high risk for heart disease. The goal is to see if these treatments help achieve specific cholesterol targets.

High Cholesterol≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Breast Cancer: MK-2870 with or without Pembrolizumab

We are comparing a new treatment for advanced breast cancer that can't be surgically removed to standard chemotherapy. This study aims to see if the new treatment improves outcomes for patients.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Breast Cancer Treatment: Elacestrant with Olaparib

We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Heart Failure: Stopping Medication After Cardiac Resynchronization Therapy

We are studying the effects of withdrawing medication in patients who have improved heart function after cardiac resynchronization therapy. This trial will help us understand the safety and changes in heart health when treatment is stopped.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Quizartinib for Pediatric FLT3-ITD Positive AML

We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.

Pediatric Acute Myeloid Leukemia (AML)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Prostate Cancer: New Treatment Combining Radiation and Antiandrogen

We are studying a new treatment approach for men with advanced prostate cancer to see if combining radiation therapy with a second-generation antiandrogen improves outcomes. The trial will also look at quality of life and any side effects from the treatment.

Oligometastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology